Clinical trials: Allogeneic Disease
Retinitis Pigmentosa
Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II
The study will perform UC-MSCs and CM transplantation. There are two groups with different dosages. The first group will be transplanted with 1.5 million cells, meanwhile, the second group is 5 million cells.
- Trial name
- NCT05909488
- Testing
- 1.5 x 10^6 UC-MSC + CM, 5 x 10^6 UC-MSC + CM
- Where
- Indonesia
- Volunteers
- 30 people
- Sponsor
- PT. Prodia Stem Cell Indonesia
Hematologic Cancer, Relapse Leukemia
Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)
This study will evaluate the safety of infusing an anti-MiHA T cell line in patients suffering from an hematologic malignancy that has relapsed following hematopoietic stem cell transplantation from a matched donor.
- Conditions
- Hematologic Cancer, Relapse Leukemia, Relapsed Adult ALL, Relapsed Adult AML
- Trial name
- GLIDE (NCT03091933)
- Testing
- GLIDE
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
GVHD, Chronic
Improvement of Women's Health After Allogeneic Stem Cell Transplantation
The aim of this prospective research project is to better understand vulvovaginal cGVHD to improve care of allografted women. The expected outcomes include better knowledge of the incidence and manifestations of vulvovaginal…
- Trial name
- SaFeGreff (NCT06279676)
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
Acute Myeloid Leukemia
Sorafenib In Relapse of FMS-like Tyrosine Kinase 3 (FLT3)-Internal Tandem Duplication (ITD) AML Trial
In this trial the investigators will evaluate the outcomes of 4 pre-defined groups of individuals according to the therapeutic intervention.
- Trial name
- SIRA (NCT02867891)
- Volunteers
- 396 people
- Sponsor
- Robert Zeiser
CD19+ Malignancies: Relapse Post-allogeneic Transplant
CAR19 Donor Lymphocytes for Relapsed CD19+ Malignancies Following Allogeneic Transplantation
Eligible patients will receive escalating doses of 4G7-CARD T-cells paralleling clinical standard of care with unmanipulated donor lymphocytes. There are 3 intra-patient dose levels planned.
- Trial name
- CARD (NCT02893189)
- Testing
- Infusion of modified CAR19 T-cells (4G7-CARD T-cells)
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- University College, London
Multiple Sclerosis
Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis
The goal of this research study is to establish chimerism with the goal to halt disease progression in patients with Multiple Sclerosis.
- Trial name
- NCT00497952
- Testing
- hematopoetic stem cell infusion
- Sponsor
- Talaris Therapeutics Inc.
Leukemia, Hodgkin's Lymphoma
Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related Illness Following Total Body Irradiation and Stem Cell Transplant
The purpose of this study is to better understand why some women who survived cancer or a related illness later develop diabetes, problems with their cholesterol, or other problems that may lead to heart disease.
- Conditions
- Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Myelodysplastic Syndrome
- Trial name
- NCT00510315
- Testing
- Questionnaires, Laboratory tests, Abdominal MRI
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Graft Vs Host Disease, Vitamin A Deficiency
Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.
The investigators hypothesize that single oral high dose supplementation with vitamin A will reduce the incidence of moderate-severe chronic graft-versus-host disease (GVHD) compared with placebo.
- Conditions
- Graft Vs Host Disease, Vitamin A Deficiency, Vitamin D Deficiency
- Trial name
- NCT06450925
- Testing
- Vitamin A
- Where
- 3 sites in United States
- Volunteers
- 190 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Ischemic Stroke
A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke
The purpose of this study is to assess the safety and tolerability of allogeneic adult mesenchymal bone marrow cells administered intravenously to patients with ischemic stroke.
- Trial name
- NCT01297413
- Testing
- Allogeneic adult mesenchymal bone marrow stem cells
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Stemedica Cell Technologies, Inc.
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Vitamin A and D Supplementation in Allogeneic HCT
The therapy under investigation is the addition of 300 000 IU of vitamin A and 100 000 IU of vitamin D before conditioning. The study will include patients with malignant diseases in hematologic response with indications for…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Biphenotypic Acute Leukemia, Lymphoblastic Lymphoma
- Trial name
- VitaStem (NCT06508099)
- Testing
- Vitamin A, Vitamin D3
- Where
- Russia
- Volunteers
- 220 people
- Sponsor
- St. Petersburg State Pavlov Medical University
VZV Infection After Bone Marrow Transplantation
Long-Term Oral Acyclovir Usage to Prevent Herpes Zoster Virus Infection After Bone Marrow Transplant
The objective of this study is to prevent reactivation of herpes zoster during the first year after transplant.
- Trial name
- NCT00209352
- Testing
- Acyclovir
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Fred Hutchinson Cancer Center
Hematologic Malignancies, Nonmalignant Diseases
Study of Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation
Fludarabine is a chemotherapy drug used extensively in bone marrow transplantation. The goal of this study is to determine what causes some children to have different drug concentrations of fludarabine in their bodies and if drug…
- Conditions
- Hematologic Malignancies, Nonmalignant Diseases, Immunodeficiencies, Hemoglobinopathies
- Trial name
- HCT (NCT01316549)
- Testing
- Fludarabine
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- University of California, San Francisco
Acute Gastrointestinal Graft-versus-host Disease
Prospective Randomized Controlled Study: Amimaitosai Injection Combined With Corticosteroids for Gastrointestinal aGVHD
This study focuses on patients with gastrointestinal-dominant acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation.
- Trial name
- NCT07803978
- Testing
- Amimaitosai injection, Methylprednisolone
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chinese PLA General Hospital
Aplastic Anemia
Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia
Primary Objectives: 1. To determine the feasibility and toxicity of employing purine-analog based conditioning for allogeneic donor stem cell transplantation in patients with severe aplastic anemia (AA). 2.
- Trial name
- NCT00427336
- Testing
- Fludarabine, Cyclophosphamide, Antithymocyte Globulin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- M.D. Anderson Cancer Center
Graft Versus Host Disease, GVHD
Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention
This study will test PANO in combination with tacrolimus/sirolimus (TAC/SIR) for acute GVHD prevention. The purpose of this study is to determine if Panobinostat (PANO) when used in combination with sirolimus and tacrolimus will…
- Trial name
- NCT02588339
- Testing
- Panobinostat, Sirolimus, Tacrolimus
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Epidermolysis Bullosa
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over)
The aim of this clinical trial is to investigate the safety and efficacy of allo-APZ2-OTS administered intravenously to subjects with recessive dystrophic epidermolysis bullosa (RDEB) compared to placebo.
- Trial name
- NCT05464381
- Testing
- allo-APZ2-OTS
- Where
- 16 sites in Argentina, Austria and 10 more
- Volunteers
- 91 people
- Sponsor
- RHEACELL GmbH & Co. KG
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer
RATIONALE: Giving chemotherapy drugs, such as busulfan and etoposide, and intensity-modulated radiation therapy before a donor stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Trial name
- NCT00540995
- Testing
- busulfan, etoposide, intensity-modulated radiation therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
Multiple Myeloma
Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma
The purpose of this study is to test the safety of specialized white cells from the donor at different doses. They are called WT1 sensitized T cells. They have been grown in the lab and are immunized against a protein.
- Trial name
- NCT01758328
- Testing
- busulfan, melphalan, fludarabine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia
This multicenter, prospective phase III-study is to compare the administration of ATG FRESENIUS to the NON-administration of ATG FRESENIUS in a myeloablative conditioning regimen followed by allogeneic hematopoeitic stem cell…
- Trial name
- NCT00678275
- Testing
- ATG FRESENIUS (Anti-Lymphocyte-Globulin)
- Where
- Germany
- Volunteers
- 161 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Hematopoetic Stem Cell Transplant
A Multicenter Phase I Study Evaluating the Addition of Bortezomib to an Established Acute Graft Versus Host Disease Prophylaxis Regimen in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Patients
The objective of this study is to determine the maximum tolerated dose (MTD) of bortezomib in combination with calcineurin inhibitor and methotrexate as acute graft versus host disease (aGVHD) prophylaxis in pediatric patients…
- Trial name
- NCT01926899
- Testing
- Bortezomib administration
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Indiana University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.